Jefferies raised the price target for the Inozyme Pharma Inc. (NASDAQ:INZY) stock to “a Hold”. The rating was released on May 26, 2022, according to finviz. The research report from Needham has initiated the stock to Buy, with a price target set at $23. The stock was initiated by Wedbush, who disclosed in a research note on August 18, 2020, to Outperform and set the price objective to $35. In their research brief published August 18, 2020, Piper Sandler analysts initiated the Inozyme Pharma Inc. stock to Overweight with a price target of $40.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Inozyme Pharma Inc. (NASDAQ:INZY) raised 4.73% to close Wednesday’s market session at $1.55, higher as compared to yesterday’s close. The stock price fluctuated between $1.50 and $1.6063 throughout the trading session with the volume trading being 448688 shares, which represented a significant variation when compared to the three months average volume of 66.77K shares. The firm’s stock price fluctuated -1.27% within the last five trades and -29.86% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -61.25% in the last 6 months and -55.46% was subtracted to its value over the previous 3 months. INZY stock is trading at a margin of -6.46%, -31.77% and -59.95% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, INZY deals in the Healthcare domain. The stock is trading -83.28 percent below its 52-week high and 6.90 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -81.5. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Inozyme Pharma Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $62.00 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 0.50, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.90 percent of Inozyme Pharma Inc. shares are owned by insiders, and 86.70 percent are held by financial institutions. Pivotal bioVenture Partners Fu, the Director at Inozyme Pharma Inc. (INZY) has bought 1,070,000 shares of firm on Apr 19 at a price of $3.69 against the total amount of $3.95 million. In another inside trade, Subramanian Sanjay, SVP, CFO of Inozyme Pharma Inc. (NASDAQ:INZY) bought 27,100 shares of the firm on Apr 19 for a total worth of $99999.0 at a price of $3.69. An inside trade which took place on Apr 19, Director of Inozyme Pharma Inc. Hopfner Robert Lorne bought 1,070,000 shares of firm against total price of $3.95 million at the cost of $3.69 per share.